Rivoceranib FDA Approval Status

Last updated by Judith Stewart, BPharm on May 31, 2023.

FDA Approved: No
Generic name: rivoceranib
Company: Elevar Therapeutics, Inc.
Treatment for: Hepatocellular Carcinoma

Rivoceranib is an oral tyrosine kinase inhibitor (TKI) in development for the treatment of hepatocellular carcinoma.

Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Rivoceranib works in the treatment of solid tumors by inhibiting VEGF-induced endothelial cell migration and proliferation, and thus inhibiting the angiogenesis essential for tumor growth and survival.
Clinical studies for rivoceranib are in progress for multiple solid tumor indications including unresectable hepatocellular carcinoma (in combination with camrelizumab), gastric cancer (as a monotherapy and in combination with paclitaxel), adenoid cystic carcinoma (as a monotherapy), and colorectal cancer (in combination with Lonsurf^®).

Development timeline for rivoceranib

Date	Article
Jul 17, 2023	Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
May 17, 2023	Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
Nov 11, 2021	Elevar Therapeutics Receives Orphan Drug Designation from FDA for Rivoceranib for the Treatment of Hepatocellular Carcinoma (HCC)

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.